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The collection, storage and use of genomic and clinical data from patients and
healthy individuals is a key component of personalised medicine enterprises
such as the Precision Medicine Initiative, the Cancer Moonshot and the
100,000 Genomes Project. In order to maximise the value of this data, it is
important to embed a culture within the scientific, medical and patient commu-
nities that supports the appropriate sharing of genomic and clinical infor-
mation. However, this aspiration raises a number of ethical, legal and
regulatory challenges that need to be addressed. The Global Alliance for Geno-
mics andHealth, aworldwide coalitionof researchers, healthcare professionals,
patients and industry partners, is developing innovative solutions to support
the responsible and effective sharing of genomic and clinical data. This article
†This article is informed by a presentation entitled ‘Sharing clinical and genomic data in cancer: aspiration versus reality’
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identifies the challenges that a data sharing culture poses andhighlights a series
of practical solutions that will benefit patients, researchers and society.
keywords personalised medicine, big data, data sharing, genomics, cancer,
bioethics
A cautionary tale: bioethics and the discovery of ‘the secret of life’
Sharing data can lead to new knowledge, but what about consent?
In the Eagle Pub in Cambridge in England, a metal plaque on the wall bears the
following inscription:
On this spot, on February 28th 1953, Frances Crick and James Watson made the first
public announcement of the discovery of DNA, with the words ‘We have discovered
the secret of life’.
This of course led to their landmark paper in Nature (Watson and Crick 1953) in
1953 and the subsequent award of the Nobel Prize for Physiology or Medicine to
Crick, Watson and their colleague Maurice Wilkins in 1962.
A second plaque, slightly lower down on the same wall, has the following epitaph:
In memory of Rosalind Franklin (Newnham College 1938–1941) whose exceptionally
skilled crystallography enabled Crick and Watson to unravel the double helix structure
of DNA. Tragically she died before the Nobel Prize was awarded. Her contribution was
not fully recognised until much later
Franklin’s key contribution was ‘Photograph 51’, the nickname given to the X-ray
diffraction image taken by her and her PhD student Raymond Gosling in May
1952. This iconic image was subsequently shown by Maurice Wilkins (without
Franklin’s knowledge or more importantly her consent) to Watson and Crick,
who recognised its significance and began building potential models that captured
the double helical structure of Deoxyribonucleic acid (DNA), leading to their pro-
phetic announcement in the Eagle Pub some 9 months later.
Secondary use of data: parasitism or symbiosis
Viewing this somewhat controversial aspect of the discovery of DNA through a
bioethics prism highlights the challenges that genetic/genomic research has faced
and continues to experience in the context of data generation and its (myriad)
uses. Spinning the helix forward to 2016, the rather unfortunate characterisation
of secondary users of data as ‘research parasites’ by Dan Longo and Jeffrey
Drazen (deputy editor and editor of the New England Journal of Medicine respect-
ively) (Longo and Drazen 2016a) led to a series of letters to the editors of a number
of medical and scientific journals (including the New England Journal of Medicine)
and a series of blogs on the issue, prompting a more nuanced reassessment by Longo
and Drazen of the relationship between primary data producers and data (re)ana-
lysts (Longo and Drazen 2016b). A number of key questions include — Who
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owns the data? How can it be used? How do we preserve the rights of the original
data source/ data generator? All are highly pertinent to medical research and its clini-
cal translation and need to be addressed.
Data sharing at scale: big science, big data and big challenges
Data mining and the potential for data sharing form a key component of a number
of recent high profile genomics/personalised medicine initiatives that also have
significant clinical potential. In his State of the Union address in 2015, former US
President Barack Obama announced his intention to launch the Precision Medicine
Initiative (PMI) (The White House, https://www.whitehouse.gov/the-press-office/
2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative), an innova-
tive programme which aims to move away from the ‘one size fits all’ approach for
therapeutic intervention and employ a more precise knowledge of the genomic, clini-
cal and epidemiological characteristics of the patient’s individual disease to inform
treatment decision-making. As part of the initiative and with specific reference to
cancer, he highlighted the need for the development of a ‘cancer knowledge
network’ as the ideal mechanism to best manage and utilise the huge amount of
data that will be generated through PMI.
Cancer was also very much the focus of then US Vice President Joe Biden when he
was addressing the American Society for Clinical Oncology Conference in Chicago
last June. Speaking of his vision for the Cancer Moonshot (ASCO, http://am.asco
.org/vice-president-joe-biden-discusses-cancer-moonshot-initiative-during-asco-2016)
an initiative to accelerate cancer research, such that this killer disease can be either pre-
vented, detected earlier or treated more successfully, he announced the launch of the
National Cancer Institute’s Genomic Data Commons (NCI-GDC) (NIH, https://www
.nih.gov/news-events/news-releases/newly-launched-genomic-data-commons-facilitat
e-data-clinical-information-sharing;Grossman et al. 2016), a valuable research
resource that contains significant quantities of data from NCI sponsored research,
with over four petabytes of data initially being released to the global cancer commu-
nity to allow comprehensive mining of this information.
Two recent research publications with clear clinical relevance have reported on the
linkage of genomic data from 50,000 patients with their Electronic Health Records
(EHRs). This work forms part of the DiscoverEHR study of the Geisinger MyCode
Community Health initiative and highlight the ability to combine DNA sequencing
data with clinical information to identify novel therapeutic targets, in this case par-
ticularly in cardiovascular diseases (Abul-Husn et al. 2016; Dewey et al. 2016).
In the UK, the 100,000 Genomes Project, an initiative that was introduced by
ex-Prime Minister David Cameron, is generating significant amounts of genomic
and clinical data that will inform disease diagnosis and treatment decision-making,
particularly for rare diseases and cancer (Siva 2015). There are similar national
efforts at different stages of development across the world.
However, for all of these initiatives, there are many challenges, including signifi-
cant ethical and legal issues that need to be addressed, in order to ensure that data is
shared and utilised in an appropriate fashion.
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Ensuring responsible and effective sharing of data: the Global
Alliance for Genomics and Health
So how do we ensure, at an international level, that data sharing which is
beneficial to the individual and to society can occur, in a way in which the
rights of the individual (and/or the data producer) are appropriately
addressed and the legal and ethical responsibilities are clearly delineated?
The Global Alliance for Genomics and Health (GA4GH) (Global Alliance for Geno-
mics and Health, https://genomicsandhealth.org/about-the-global-alliance/key-
documents/white-paper-creating-global-alliance-enable-responsible-shar;Global
Alliance for Genomics and Health et al. 2016) is an international coalition of life and
data scientists, clinicians, patients and their advocates and information technology/
bio industry partners, dedicated to promoting responsible and effective sharing of
genomic and clinical data. Since its inaugural conference in the Welcome Trust in
London in 2013, GA4GH has grown significantly and now has over 450 insti-
tutional members from >60 countries (Global Alliance for Genomics and Health,
https://genomicsandhealth.org/members), with a clear focus on genomic and clinical
data sharing in rare disease and in cancer, and an emerging interest in infectious
disease. The activities of GA4GH are mediated through four Working Groups:
The Clinical Working Group, the Data Working Group, the Regulatory and
Ethics Working Group and the Security Working Group. In addition, a series of
Task Teams, dedicated to particular issues or challenges, develop and deliver par-
ticular projects, scientific and policy papers and tools/solutions that promote and
simplify the sharing of data.
Changing the mindset: from selfish silo to collaborative culture
One of the challenges that can undermine effective linking of multiple sources of
information is when the data repositories that would benefit from being interlinked
and appropriately mined to deliver added value, instead sit in siloed isolation with
no ability to ‘talk’ to each other (Lawler et al. 2015). Establishing a flourishing
data sharing culture in diseases such as cancer also requires a collective change in
the individual researcher mindset, moving away from this closed ‘selfish silo’
approach to embrace a more ‘open source’ collaborative culture. Reluctance to
share data in academia is, in some cases, influenced by perceptions of loss of
control and dilution of credit in multi-author studies. The pressures of increased
competition for research funding and the need for senior authored research
papers to satisfy institutional academic standards, allied to the contribution of
these two metrics to support applications for academic promotion, can negatively
affect the appetite of researchers to pool data for mutual benefit. However,
working together in data sharing projects enhances scientific rigour, increases the
statistical power of the particular study and delivers rich sources of reliable data.
Ensuring credit for collaborative data sharing efforts can be facilitated using appro-
priate microattribution-based credits (Patrinos et al. 2012), (akin to a ‘Genomic
Bitcoin’) such that data producers and data consumers both receive fair reward
for their research contribution and effort. An even greater resistance to data
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sharing has pervaded bio-industry, leading to unnecessary duplication of effort,
which in a number of cases, has yielded negative results (Turner et al. 2008),
wasting millions of dollars and precious patient resources, while delivering little dis-
cernable clinical benefit. In this regard, the Innovative Medicines Initiative (IMI), the
public private partnership between the European Commission and Industry is
driving an initiative that is breaking down some of these data silos. Through its
Big Data for Better Health funding programme (Innovative Medicines Initiatives,
http://www.imi.europa.eu/content/imi-2-call-6-launch), industry and academia are
working together to share data in order to maximise its value in enhancing
human health. The Structural Genomics Consortium (http://www.thesgc.org/) rep-
resents another public private partnership, between six academic institutions and
industry, promoting an open access research culture that shares the fruits of its
labour in developing new medicines through an ‘Innovation for All’ philosophy.
Ensuring ethical rigour: the framework for responsible sharing of
genomic and health related data
Data sharing, particularly across different countries/jurisdictions may be challenging
within a traditional ethics framework, particularly given the global diversity in legal
and regulatory requirements. Additionally, potential privacy issues may be more
prevalent, given the ability of genetic material to identify an individual person or a
member of their family. To ensure that data sharing efforts and cross border open
source collaborative approaches are developed and applied with appropriate ethical
rigour, GA4GH has considered ethical issues from a fundamental human rights per-
spective, by developing a Framework for Responsible Sharing of Genomic and
Health Related Data (Global Alliance for Genomics and Health, https://genomicsand
health.org/about-the-global-alliance/key-documents/framewor
k-responsible-sharing-genomic-and-health-related-data). This perspective extends the
traditional bioethics approach within a harmonised framework that preserves the
rights of the individual, but addresses current ‘NoCanDo’ defensive data access prac-
tices by firmly espousing the ‘YesWeCan’ right of the individual (patient or researcher)
to benefit from the increased outputs of research, mediated through appropriate and
secure data sharing solutions. Employing a legal human rights perspective can circum-
vent many of the challenges that a traditional ethics frameworkmay present, position-
ing genomic and clinical data sharing within an international legal framework that
provides support for data sharing for the benefit of patients, thus encouraging adher-
ence to the Framework principles by all stakeholders while offering legal protection to
patients in areas such as fair access, privacy and discrimination (Knoppers 2014).
Underpinning this Framework are a series of overarching ethics policies. These
include the GA4GH Consent Policy (Global Alliance for Genomics and Health,
https://genomicsandhealth.org/consent-policy-pdf-27-may-2015), which provides
useful guidance on the principles and practice of ensuring appropriate consent in
different data sharing scenarios. In addition, GA4GH has created something akin
to a Data Sharing Ethics ‘Toolbox’, which includes the following consent tools (i)
A Legacy Consent and International Data Sharing Tool (GA P3G-IPAC Consent
Tools, https://genomicsandhealth.org/ga-p3g-ipac-consent-tools) which addresses
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the issue of consents that were taken at the time of the original study, but which may
not have considered/envisaged the diversity and complexity of future scientific use(s)
of samples or data); (ii) A Generic International Data Sharing Prospective Consent
Form (GA P3G-IPAC Consent Tools, https://genomicsandhealth.org/
ga-p3g-ipac-consent-tools) which provides a readily adaptable consent template
for international data sharing approaches for prospective studies; and (iii) A series
ofClauses for International Data Sharing (GA P3G-IPAC Consent Tools, https://gen
omicsandhealth.org/ga-p3g-ipac-consent-tools) which contribute both useful advice
and a series of templates for researchers who wish to add appropriate clauses or
addendums in relation to international data sharing to their existing consent docu-
ment(s). Portable and/or electronic consent tools are also under development. These
policies and tools help deliver appropriate support, advice and relevant templates for
researchers to ensure that their data sharing activities are conducted with due respect
to rigorous ethical and legal principles.
GA4GH’s Regulatory and Ethics Working Group has produced both a Privacy
and Security Policy (Global Alliance for Genomics and Health, https://genomicsand
health.org/privacy-and-security-policy-pdf-26-may-2015) and a ‘safe harbor’mech-
anism for privacy protection (Knoppers et al. 2014), which can be tailored to
address particular scenarios such as those in relation to cross-border data sharing
(Siu et al. 2016). In addition, the GA4GH Security Working Group has created a
Security Infrastructure Policy Paper (Global Alliance for Genomics and Health,
https://genomicsandhealth.org/security-infrastructure-version-11) which specifically
address privacy and security concerns, delineating the appropriate standards and
implementation practices that are required in order to protect the privacy and secur-
ity of shared genomic and clinical data.
Data repository and data analysis solutions: centralised versus
federated approaches
A second relevant area that has been considered by the GA4GH data sharing commu-
nity is the requirement for a trusted data sharing environment, which allows linking of
databases in different countries/jurisdictions through a common network. This is
especially relevant given the increasingly complex legal environment that can limit
transfer of data across borders. Rather than moving the data between countries/juris-
dictions, GA4GH’s guiding principle is that the data repositories stay in the location
where they have been generated (i.e. a federated rather than a centralised approach)
and appropriate analysis tools are ‘ported’ to the data and perform their analysis
‘on site’. In this way, data privacy and security of the primary dataset are ensured,
thus satisfying any ethical/legal concerns of the data hosting institution or consortium,
while the data consumer is able to perform appropriate analysis on the rich infor-
mation source. At a technical level, GA4GH has also developed a series of analysis
tools including the GA4GH Application Programing Interface (API) (Global Alliance
for Genomics and Health, https://genomicsandhealth.org/work-products-
demonstration-projects/genomics-api), which provides common web based protocols
to help in data sharing and analysis efforts.
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Free the data — cancer patients want their data to be shared
Critical to the establishment of a vibrant data sharing culture is the cancer patient. As
highlighted in the European Cancer Patient’s Bill of Rights (Lawler et al. 2014) when it
was launched in the European Parliament in Strasbourg on World Cancer Day 2014
(European Cancer Concord, http://www.europeancancerconcord.eu/), it is becoming
clear that cancer patients are no longer passive recipients in both research and its clini-
cal translation but are increasingly becoming active participants. Despite the potential
challenges that the recently approved General Data Protection Regulation presents to
performing research involving patients (and indeed healthy individuals) in Europe
(European Commission, http://ec.europa.eu/justice/data-protection/document/review
2012/com_2012_11_en.pdf), there is increasing evidence that cancer patients want
their data to be shared (www.free-the-data.org/) (Lin et al. 2004; Rogith et al.
2014). In addition, a number of cancer patient communities are now self-aggregating
online to share their genomic data, in the hope of developing patient-led clinical trials,
particularly for rarer mutations that may be targetable by a personalised medicine
approach (GRACE, http://cancergrace.org/lung/2016/07/08/asco-2016-can-online-
patient-groups-speed-the-development-of-new-targeted-therapies/). As patients
increasingly provide their tissues and their data to enhance scientific research from
which they individually, in the majority of cases, will not benefit, there is now a
moral imperative to ensure that the research community follows suit, and desists
from hoarding data in scientific silos, in favour of an open access collaborative
approach that maximises the value of the research data generated. Academic research
is predominantly supported through public funding, prompting funding agencies to
increasingly require that the data generated is made available through open access
as quickly as possible to the scientific community.
In conclusion, sharing data in a common disease such as cancer raises complex
ethical issues that need to be addressed in a sensitive and appropriate fashion.
However, by involving all stakeholders in what might be termed a ‘coalition of
the willing’ and ensuring that appropriate ethical frameworks are developed and rig-
orously applied, we can provide a conduit for the responsible and effective sharing of
genomic and clinical data for the benefit of patients, researchers and society.
Related video
Avideo linked to this paper can be found at: http://www.healthcarevalues.ox.ac.uk/
mark-lawler-data-sharing-and-participation
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